Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021

CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) program are being reported at the virtual American Association for Cancer Research (AACR)...

from PR Newswire: https://ift.tt/3t4F2lX